7/11/2023 | SP | New Issue: GS Finance sells $1.34 million buffered basket-linked notes on basket of 44 stocks
|
6/1/2022 | CVLM | Neurocrine Biosciences buys back more 2.25% convertibles due 2024
|
5/25/2022 | CVLM | Neurocrine Biosciences buys back $179.4 million of 2.25% convertibles
|
4/22/2022 | SP | New Issue: GS Finance sells $8 million basket-linked notes tied to 45 stocks
|
11/19/2020 | CVLM | Neurocrine to repurchase $83 million 2.25% convertible notes due 2024
|
11/19/2020 | CVLM | Neurocrine to repurchase $83 million of 2.25% convertible notes
|
9/14/2020 | CV | Market Commentary: Neurocrine Biosciences convertible notes gain; Ares Capital, Western Digital active
|
9/14/2020 | CV | Market Commentary: Morning Commentary: Ares Capital, Neurocrine Biosciences convertible notes active
|
12/11/2019 | SP | New Issue: Morgan Stanley prices $1.53 million contingent income autocalls on stocks
|
12/9/2019 | SP | New Issue: Morgan Stanley prices $1.05 million contingent income autocalls on three stocks
|
11/22/2019 | SP | Morgan Stanley plans to price contingent income autocalls on stocks
|
9/9/2019 | PF | Market Commentary: Duke Energy, South Jersey tap market; Capital One preferreds weaker; Public Storage rises
|
9/9/2019 | CV | Market Commentary: Convertibles trade in line on swap; profit taking strikes a few names; Insulet drops with shares
|
9/9/2019 | CV | Market Commentary: Morning Commentary: Profit-taking strikes convertibles of Neurocrine, Blackstone, Ionis
|
7/30/2019 | CV | Market Commentary: RingCentral, NXP Semiconductors, Neurocrine Biosciences, Ligand active post-earnings
|
4/29/2019 | CV | Market Commentary: JPMorgan’s Voya-linked notes top par; Tesla remains in focus; Momo drops outright
|
4/29/2019 | CV | Market Commentary: Morning Commentary: JPMorgan’s Voya-linked notes top par; Neurocrine Biosciences active
|
4/11/2019 | CV | Market Commentary: PAR Technology convertible notes expand; Intercept down outright, up on hedge; biotechs active
|
1/8/2019 | CV | Market Commentary: Market eyes Colfax mandatory convertible offering; Illumina expands; Intel active
|
12/12/2018 | CV | Market Commentary: Medicines on tap; Neurocrine Biosciences expands; Splunk tops par; Tilray yield crosses 11%
|
12/12/2018 | CV | Market Commentary: Morning Commentary: Neurocrine Biosciences convertibles eyed on clinical trial failure
|
7/12/2017 | CV | Market Commentary: Morning Commentary: Liquidity limited amid little news to move markets; Tesla firms with stock
|
5/2/2017 | CV | Neurocrine greenshoe increases 2.25% convertibles to $517.5 million
|
5/1/2017 | CV | Market Commentary: Blackstone Mortgage in market; recent deals in play; BroadSoft hit post-earnings
|
5/1/2017 | CV | Market Commentary: Morning Commentary: Synchronoss active; Neurocrine holds in; Blackstone Mortgage in market
|
4/27/2017 | CV | Market Commentary: New convertibles from Flexion, Neurocrine jump over par post-pricing; Synchronoss suffers
|
4/27/2017 | CV | Market Commentary: Morning Commentary: New deals from Flexion, Neurocrine jump over par post-pricing
|
4/26/2017 | CV | New Issue: Neurocrine prices $450 million 2.25% seven-year convertible notes, up 42.5%
|
4/26/2017 | CV | Market Commentary: Twitter tops estimates, convertibles flat; Anthem firms on earnings; new deals on tap
|
4/26/2017 | CV | Market Commentary: Morning Commentary: Twitter beats estimates but little changed; Flexion, Neurocrine deals in focus
|
4/25/2017 | CV | Market Commentary: Flexion, Neurocrine add deals to calendar; Tesla, InterDigital little moved ahead of earnings
|
4/25/2017 | CV | Neurocrine offers $450 million seven-year convertible notes to yield 2.5%-3%, up 37.5%-42.5%
|
1/19/2012 | PP | Neurocrine prices $76.95 million public offering of its stock at $8.10
|
1/18/2012 | PP | Neurocrine Biosciences registers public offering of its common stock
|
12/17/2009 | PP | New Issue: Neurocrine Biosciences arranges $10 million private placement of shares
|
9/15/2009 | PP | New Issue: Neurocrine arranges $75 million committed equity financing facility
|
11/16/2006 | BT | Bear Stearns ups Neurocrine to peer perform
|
11/14/2006 | BT | Neurocrine says two data re-analyses are all that block indiplon capsule approval
|
11/3/2006 | BT | Neurocrine maintained at sell by Merrill
|
10/10/2006 | BT | Market Commentary: AnorMED gains 5% as Genzyme bests Millennium bid; DOV sinks 9% on hiring HSBC, up after close
|
9/19/2006 | BT | Neurocrine names Gorman COO, Coughlin CFO, Hawran to retire
|
9/12/2006 | BT | Neurocrine says trial of endometriosis treatment met primary endpoint
|
9/5/2006 | BT | Neurocrine at sell by Merrill
|
9/5/2006 | BT | Neurocrine plans additional indiplon study to support FDA application
|
8/17/2006 | BT | Market Commentary: Neurocrine adds 10%; NPS up on 'Soros factor'; Vivus higher; Genitope slides 4%
|
8/8/2006 | BT | Neurocrine lays off 100 employees
|
7/27/2006 | BT | Neurocrine kept at sell by Merrill
|
7/26/2006 | BT | Market Commentary: DOV comes off highs; Neurocrine extends losses after hours; bird flu stocks fly; NicOx rises
|
7/26/2006 | BT | Neurocrine lays off sales force
|
7/18/2006 | BT | Neurocrine reiterated at sell by Merrill
|
7/18/2006 | BT | Market Commentary: Tercica up 12%, Insmed rises 9%; Neurocrine closes weaker; Pharma Product up; New River deal emerges
|
7/17/2006 | BT | Neurocrine reports $27.4 million net loss for second quarter
|
7/10/2006 | BT | Market Commentary: Connetics drops 33% on lowered forecast; Antigenics off 5%; Depomed off; Acadia gains
|
7/6/2006 | BT | Market Commentary: Par shares plunge, convertible up with restatement; Savient up on new CFO; Gene Logic moves up
|
7/5/2006 | BT | Market Commentary: DOV seesaws on CEO exit, closes higher; Neurocrine slides further; Insmed drops 8%; Tercica off 1%
|
6/27/2006 | BT | Market Commentary: Insmed drops 11%; Vasogen up slightly; Anadys falls more; DOV, Discovery Labs up; Genelabs gains
|
6/26/2006 | BT | Market Commentary: Vasogen plunges 74%; Anadys falls 45%; Nastech, Amylin gain on pact; Neurocrine finds buyers
|
6/23/2006 | BT | Neurocrine kept at sell by Merrill
|
6/23/2006 | BT | Market Commentary: Neurocrine, DOV fall on Pfizer nixing indiplon funding; Endo rises 10%, Penwest gains 37%
|
6/22/2006 | BT | Neurocrine, Pfizer end collaboration on indiplon, Neurocrine to develop independently
|
6/19/2006 | BT | Neurocrine kept at sell by Merrill
|
6/19/2006 | BT | Market Commentary: Peregrine up; Micrus off; DOV drops 11%; Neurocrine off 7%; American Medical plans $325 million bond
|
6/15/2006 | BT | Neurocrine to meet with FDA on Not Approvable Letter for indiplon
|
5/22/2006 | BT | Market Commentary: Adventrx gains after pulling deal; Dyax gains, Icos slips on pact; Cell Therapeutics declines 7%
|
5/19/2006 | BT | Market Commentary: Illumina gains after spot sale; Neurocrine, DOV mixed; Pozen pounded; Alkermes dips, settles higher
|
5/18/2006 | BT | Market Commentary: Neurocrine piles on more losses; DOV adds back 10%; Celgene sees buying on dip; Exelixis up
|
5/17/2006 | BT | Market Commentary: Vivus up 15%; Hana off 10% on PIPE deal; Restore gains on debut; NxStage drops on follow-on deal
|
5/16/2006 | BT | Merrill downgrades Neurocrine to sell
|
5/16/2006 | BT | Market Commentary: Neurocrine, DOV dive; Novavax, Generex dive amid noise of exits; Adventrx slips modestly on deal
|
5/16/2006 | CV | Market Commentary: American Axle surges on possible loophole; DOV Pharmaceuticals falls, Sepracor gains on drug's rejection
|
5/16/2006 | BT | Neurocrine insomnia 15 mg tablet not approved by FDA
|
5/15/2006 | BT | Market Commentary: BioMimetic goes south; Sirna off on new deal; Cambridge rockets on buyout; Threshold extends fall
|
5/12/2006 | BT | Neurocrine stays at neutral by Merrill
|
4/28/2006 | BT | Merrill keeps Neurocrine at neutral
|
4/28/2006 | BT | Market Commentary: Neurocrine drops as data digested; Somaxon higher as buyers step in; Spectranetics up; Sonus soars 8%
|
4/27/2006 | BT | Neurocrine announces positive phase 2 results with its small molecule antagonist in endometriosis
|
4/25/2006 | BT | Neurocrine kept at neutral by Merrill
|
4/25/2006 | BT | Market Commentary: Serologicals, Millipore both up; other services names dip; DOV, Discovery dive; Neurocrine off
|
4/5/2006 | BT | Neurocrine says studies show indiplon has high affinity, selectivity to sleep agent receptor
|
3/15/2006 | BT | Pharmacopeia, Neurocrine expand drug discovery, development collaboration
|
3/8/2006 | BT | Neurocrine says APL technology for multiple sclerosis fails phase 2 study; program discontinued
|
3/8/2006 | BT | Neurocrine given neutral rating by Merrill
|
3/8/2006 | BT | Market Commentary: Alexza IPO gets off; Cepheid off; Dyax deal seen; Elan, Biogen up; Neurocrine shakes off trial miss
|
1/24/2006 | BT | Merrill keeps Neurocrine at neutral
|
1/17/2006 | BT | Market Commentary: Arena gains in face of follow-on deal; deCODE spikes on diabetes discovery; Acadia, Sepracor firm
|
1/11/2006 | BT | Neurocrine maintained by Merrill at neutral
|
1/10/2006 | BT | Neurocrine supplies data to FDA showing impact of indiplon on driving
|
12/19/2005 | BT | Neurocrine: Phase 2a results show urocortin 2 increases cardiac ejection fraction in heart failure patients
|
10/25/2005 | BT | Merrill Lynch maintains Neurocrine Bioscience at neutral
|
8/12/2005 | BTCV | New Issue: Morgan Stanley prices $25 million 7.25% Perqs exchangeable for Neurocrine Biosciences
|
8/4/2005 | BT | Neurocrine reiterated by Merrill at neutral
|
7/18/2005 | BT | Neurocrine upgraded by Thomas Weisel to outperform
|